Predictive value of elevated soluble CD40 ligand in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction

Coronary Artery Disease

Volumn 25, Issue 7, 2014, Pages 558-564

  Pusuroglu, Hamdi ^a   Akgul, Ozgur ^a   Erturk, Mehmet ^a   Uyarel, Huseyin ^b   Bulut, Umit ^a   Akkaya, Emre ^a   Buturak, Ali ^c   Surgit, Ozgur ^a   Fuat, Ali ^d   Cetin, Mustafa ^e   Yildirim, Aydin ^a  

^a Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Center   (Turkey)

^b BEZMIALEM VAKIF UNIVERSITY   (Turkey)

^c ACIBADEM UNIVERSITY   (Turkey)

^d Erzurum State Research and Training Hospital   (Turkey)

^e Rize Education and Research Hospital ^*  (Turkey)

Author keywords

Myocardial infarction; Primary angioplasty; Soluble CD40 ligand

Indexed keywords

CD40 LIGAND;

ADULT; ADVERSE OUTCOME; ARTICLE; CARDIOVASCULAR MORTALITY; FEMALE; FOLLOW UP; HEART FAILURE; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TREATMENT OUTCOME; ACUTE CORONARY SYNDROME; AGED; BLOOD; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODEL; TRANSLUMINAL CORONARY ANGIOPLASTY;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANGIOPLASTY, BALLOON, CORONARY; CD40 LIGAND; FEMALE; HOSPITAL MORTALITY; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TREATMENT OUTCOME;

EID: 84927692146     PISSN: 09546928     EISSN: 14735830     Source Type: Journal    
DOI: 10.1097/MCA.0000000000000142     Document Type: Article

References (33)

1. Fox KA, Cokkinos DV, Deckers J, Keil U, Maggioni A, Steg G. The ENACT study: a pan-European survey of acute coronary syndromes. European Network for Acute Coronary Treatment. Eur Heart J 2000;21:1440-1449.
2. Fox KA, Goodman SG, Anderson FA Jr, Granger CB, Moscucci M, Flather MD, et al. GRACE Investigators. From guidelines to clinical practice: the impact of hospital and geographical characteristics on temporal trends in the management of acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2003;24:1414-1424.
3. Kolansky DM. Acute coronary syndromes: morbidity, mortality, and pharmacoeconomic burden. Am J Manag Care 2009;15(Suppl):S36-S41.
4. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995;92:657-671.
5. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med 1992;326:242-250.
6. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med 1992;326:310-318.
7. Tousoulis D, Antoniades C, Koumallos N, Stefanadis C. Pro-inflammatory cytokines in acute coronary syndromes: from bench to bedside. Cytokine Growth Factor Rev 2006;17:225-233.
8. Schönbeck U, Libby P. CD40 signaling and plaque instability. Circ Res 2001;89:1092-1103.
9. Heeschen C, Dimmeler S, Hamm CW, Van Den Brand MJ, Boersma E, Zeiher AM, et al. CAPTURE Study Investigators. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003;348:1104-1111.
10. Antoniades C, Bakogiannis C, Tousoulis D, Antonopoulos AS, Stefanadis C. The CD40/CD40 ligand system: linking inflammation with atherothrombosis. J Am Coll Cardiol 2009;54:669-677.
11. Aukrust P, Muller F, Ueland T, Berget T, Aaser E, Brunsvig A, et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 1999;100:614-620.
12. Yan J, Wu Z, Huang Z, Li L, Zhong R, Kong X. Clinical implications of increased expression of CD40L in patients with acute coronary syndromes. Chin Med J (Engl) 2002;115:491-493.
13. Schiller NB, Shah PM, Crawford M, De Maria A, Devereux R, Feigenbaum H, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989;2:358-367.
14. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function - measured and estimated glomerular filtration rate. N Engl J Med 2006;354:2473-2483.
15. Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 1987;76:142-154.
16. Killip T III, Kimball JT. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am J Cardiol 1967;20:457-464.
17. Lutgens E, Gorelik L, Daemen MJ, De Muinck ED, Grewal IS, Koteliansky VE, Flavell RA. Requirement for CD154 in the progression of atherosclerosis. Nat Med 1999;5:1313-1316.
18. Mach F, Schönbeck U, Sukhova GK, Atkinson E, Libby P. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 1998;394:200-203.
19. Garlichs CD, Eskafi S, Raaz D, Schmidt A, Ludwig J, Herrmann M, et al. Patients with acute coronary syndromes express enhanced CD40 ligand/CD154 on platelets. Heart 2001;86:649-655.
20. Undas A, Stepien E, Branicka A, Wolkow P, Zmudka K, Tracz W. Thrombin formation and platelet activation at the site of vascular injury in patients with coronary artery disease treated with clopidogrel combined with aspirin. Kardiol Pol 2009;67:591-598.
21. Dündar C, Kizilirmak F, Tigen K, Izgi A, Karaahmet T, Pala S, et al. Soluble CD40 ligand release in patients with stable coronary artery disease during elective stent implantation: effect of drug-eluting stent over bare metal stent. Turk kardiyol Dern Ars 2013;41:675-682.
22. Tousoulis D, Antoniades C, Stefanadis C. Assessing inflammatory status in cardiovascular disease. Heart 2007;93:1001-1007.
23. Aggarwal A, Schneider DJ, Terrien EF, Sobel BE, Dauerman HL. Increased coronary arterial release of interleukin-1 receptor antagonist and soluble CD40 ligand indicative of inflammation associated with culprit coronary plaques. Am J Cardiol 2004;93:6-9.
24. Varo N, De Lemos JA, Libby P, Morrow DA, Murphy SA, Nuzzo R, et al. Soluble CD40L: risk prediction after acute coronary syndromes. Circulation 2003;108:1049-1052.
25. Martín-Ventura JL, Blanco-Colio LM, Tunon J, Munoz-Garcia B, Madrigal-Matute J, Moreno JA, et al. Biomarkers in cardiovascular medicine. Rev Esp Cardiol 2009;62:677-688.
26. L'Allier PL, Tardif JC, Gregoire J, Joyal M, Lespérance J, Fortier A, Guertin MC. Sustained elevation of serum CD40 ligand levels one month after coronary angioplasty predicts angiographic restenosis. Can J Cardiol 2005;21:495-500.
27. Urbich C, Dernbach E, Aicher A, Zeiher AM, Dimmeler S. CD40 ligand inhibits endothelial cell migration by increasing production of endothelial reactive oxygen species. Circulation 2002;106:981-986.
28. De Lemos JA, Zirlik A, Schönbeck U, Varo N, Murphy SA, Khera A, et al. Associations between soluble CD40 ligand, atherosclerosis risk factors, and subclinical atherosclerosis: results from the Dallas Heart Study. Arterioscler Thromb Vasc Biol 2005;25:2192-2196.
29. Morrow DA, Sabatine MS, Brennan ML, De Lemos JA, Murphy SA, Ruff CT, et al. Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. Eur Heart J 2008;29:1096-1102.
30. Tan J, Hua Q, Gao J, Fan ZX. Clinical implications of elevated serum interleukin-6, soluble CD40 ligand, metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in patients with acute ST-segment elevation myocardial infarction. Clin Cardiol 2008;31:413-418.
31. Rondina MT, Lappe JM, Carlquist JF, Muhlestein JB, Kolek MJ, Horne BD, et al. Soluble CD40 ligand as a predictor of coronary artery disease and long-term clinical outcomes in stable patients undergoing coronary angiography. Cardiology 2008;109:196-201.
32. Olenchock BA, Wiviott SD, Murphy SA, Cannon CP, Rifai N, Braunwald E, Morrow DA. Lack of association between soluble CD40L and risk in a large cohort of patients with acute coronary syndrome in OPUS TIMI-16. J Thromb Thrombolysis 2008;26:79-84.
33. Zirlik A, Maier C, Gerdes N, MacFarlane L, Soosairajah J, Bavendiek U, et al. CD40 ligand mediates inflammation independently of CD40 by interaction with Mac-1. Circulation 2007;115:1571-1580.